The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Norgesic
Orphenadrine Citrate, Aspirin and Caffeine · ORPHENADRINE CITRATE 25 mg/1; ASPIRIN 385 mg/1; CAFFEINE 30 mg/1 · Tablet · Oral · Galt Pharmaceuticals, LLC
NDC 61825-0305-60 · 60 TABLET in 1 BOTTLE, PLASTIC · ANDA · View full market →
Medicare Part D
All Part D pricing →ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$23.39per unit
middle half $23.39–$23.39 · 18 plans · Jul 1, 2024
Est. net of rebatesⓘ
≈ $23.39
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
—of plans cover it
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- ANDA075141
- TE code
- —
- Approval date
- May 29, 1998
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Orphenadrine Citrate, Aspirin and Caffeine (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 50 mg/1; ASPIRIN 770 mg/1; CAFFEINE 60 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 25 mg/1; ASPIRIN 385 mg/1; CAFFEINE 30 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 50 mg/1; ASPIRIN 770 mg/1; CAFFEINE 60 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 25 mg/1; ASPIRIN 385 mg/1; CAFFEINE 30 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 385 mg/1; ASPIRIN 30 mg/1; CAFFEINE 25 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 770 mg/1; ASPIRIN 60 mg/1; CAFFEINE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 770 mg/1; ASPIRIN 60 mg/1; CAFFEINE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 385 mg/1; ASPIRIN 30 mg/1; CAFFEINE 25 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Atland Pharmaceuticals, LLC | ASPIRIN 770 mg/1; CAFFEINE 60 mg/1; ORPHENADRINE CITRATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Atland Pharmaceuticals, LLC | ASPIRIN 385 mg/1; CAFFEINE 30 mg/1; ORPHENADRINE CITRATE 25 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Galt Pharmaceuticals, LLC | ASPIRIN 770 mg/1; CAFFEINE 60 mg/1; ORPHENADRINE CITRATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Galt Pharmaceuticals, LLC | ASPIRIN 385 mg/1; CAFFEINE 30 mg/1; ORPHENADRINE CITRATE 25 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Norgesic — NDC 61825-0305-60," retrieved September 3, 2026, https://drugdashboards.com/drug/61825030560.
Free to cite with attribution — see how the data is put together.